Strs Ohio Purchases New Shares in Agios Pharmaceuticals, Inc. $AGIO

Key Points

• Strs Ohio has acquired a new stake in Agios Pharmaceuticals, purchasing 8,200 shares valued at approximately $240,000 during the first quarter of the year.
• Several other large investors, including SCS Capital Management LLC and Goldman Sachs Group Inc., have also made significant investments in Agios Pharmaceuticals, indicating strong institutional interest in the company.
• Agios Pharmaceuticals reported a loss of ($1.93) earnings per share for the last quarter, missing the consensus estimate, but achieved revenue of $12.50 million, surpassing analysts' expectations of $9.46 million.

Strs Ohio purchased a new stake in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) during the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 8,200 shares of the biopharmaceutical company's stock, valued at approximately $240,000.

A number of other large investors also recently made changes to their positions in the company. Acadian Asset Management LLC bought a new position in shares of Agios Pharmaceuticals during the first quarter valued at about $133,000. SCS Capital Management LLC bought a new position in shares of Agios Pharmaceuticals during the first quarter valued at about $17,905,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in shares of Agios Pharmaceuticals by 19.9% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 147,276 shares of the biopharmaceutical company's stock valued at $4,315,000 after purchasing an additional 24,441 shares in the last quarter. Woodline Partners LP bought a new position in shares of Agios Pharmaceuticals during the first quarter valued at about $597,000. Finally, Goldman Sachs Group Inc. lifted its position in shares of Agios Pharmaceuticals by 16.1% during the first quarter. Goldman Sachs Group Inc. now owns 658,652 shares of the biopharmaceutical company's stock valued at $19,299,000 after purchasing an additional 91,482 shares in the last quarter.

Analyst Ratings Changes

A number of research analysts recently weighed in on the stock. HC Wainwright reissued a "buy" rating and set a $56.00 price target on shares of Agios Pharmaceuticals in a research report on Thursday, September 4th. Bank of America decreased their price objective on shares of Agios Pharmaceuticals from $52.00 to $51.00 and set a "buy" rating for the company in a report on Tuesday, July 22nd. Finally, Scotiabank decreased their price objective on shares of Agios Pharmaceuticals from $71.00 to $65.00 and set a "sector outperform" rating for the company in a report on Monday, July 28th. Six analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company's stock. According to data from MarketBeat.com, Agios Pharmaceuticals currently has an average rating of "Moderate Buy" and an average price target of $56.00.

Agios Pharmaceuticals Stock Performance

NASDAQ AGIO opened at $37.32 on Thursday. Agios Pharmaceuticals, Inc. has a 52-week low of $23.42 and a 52-week high of $62.58. The company has a 50-day simple moving average of $37.53 and a 200 day simple moving average of $33.45. The company has a market capitalization of $2.17 billion, a PE ratio of 3.39 and a beta of 0.87.

Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last posted its earnings results on Thursday, July 31st. The biopharmaceutical company reported ($1.93) earnings per share for the quarter, missing the consensus estimate of ($1.74) by ($0.19). The business had revenue of $12.50 million during the quarter, compared to analysts' expectations of $9.46 million. Agios Pharmaceuticals had a negative return on equity of 3.49% and a net margin of 1,590.42%. As a group, analysts forecast that Agios Pharmaceuticals, Inc. will post -6.85 EPS for the current fiscal year.

Insider Buying and Selling at Agios Pharmaceuticals

In other news, CEO Brian Goff sold 11,085 shares of Agios Pharmaceuticals stock in a transaction dated Friday, August 8th. The shares were sold at an average price of $36.67, for a total value of $406,486.95. Following the completion of the transaction, the chief executive officer owned 123,528 shares in the company, valued at $4,529,771.76. This trade represents a 8.23% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director David Scadden sold 1,400 shares of Agios Pharmaceuticals stock in a transaction dated Thursday, July 10th. The stock was sold at an average price of $40.00, for a total transaction of $56,000.00. Following the completion of the transaction, the director owned 17,603 shares of the company's stock, valued at $704,120. The trade was a 7.37% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 37,036 shares of company stock worth $1,369,980 over the last three months. Company insiders own 4.30% of the company's stock.

Agios Pharmaceuticals Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.